Disruption of NUAK2‑Mediated RNA splicing by trilaciclib reveals a therapeutic vulnerability in AR‑Indifferent prostate cancer
Prostate cancer remains a leading cause of cancer-related mortality in men, with aggressive, treatment-emergent androgen receptor (AR)-indifferent subtypes, including double-negative prostate cancer (DNPC) and neuroendocrine prostate cancer (NEPC), posing major clinical challenges due to limited therapeutic options. NUAK family kinase 2 (NUAK2), an AMPK-related kinase, has been implicated in tumor growth and metastatic progression; however, its functional significance and therapeutic potential in advanced prostate cancer remain largely unexplored. Here, we identify NUAK2 as a therapeutically actionable kinase dependency in AR-indifferent prostate cancer. Transcriptomic analyses across independent patient cohorts demonstrated progressive upregulation of NUAK2 with disease progression, with the highest expression in NEPC. Immunohistochemical analysis of clinical specimens further confirmed elevated NUAK2 protein expression in NEPC relative to prostate adenocarcinoma. Genetic loss- and gain-of-function studies established NUAK2 as a functional dependency that promotes tumor cell proliferation, clonogenic growth, and tumor growth in vivo. Mechanistically, integrated proteomic analyses revealed that NUAK2 associates with spliceosomal and RNA-processing machinery, while NUAK2 perturbation induced widespread alterations in pre-mRNA splicing programs involving genes linked to mitotic regulation and oncogenic signaling. Pharmacologic studies identified trilaciclib (G1T-28), a clinically approved CDK4/6 inhibitor, as a functionally relevant NUAK2 inhibitor that directly engages NUAK2, suppresses tumor growth, and enhances the efficacy of platinum-based chemotherapy across multiple preclinical models. Collectively, these findings uncover NUAK2 as a previously unrecognized regulator of RNA splicing and therapeutic vulnerability in AR-indifferent prostate cancer and provide a rationale for repurposing G1T-28 and developing NUAK2-directed therapeutic strategies for aggressive, treatment-refractory prostate cancer.
Authors
- Jasmine Plummer (ORCID: https://orcid.org/0000-0001-7263-350X)
- Jiaoti Huang (ORCID: https://orcid.org/0000-0003-1195-1998)
- Zachary W. Davis‐Gilbert (ORCID: https://orcid.org/0000-0002-4070-0832)
- Umar Mehraj (ORCID: https://orcid.org/0000-0001-5400-9594)
- Shaista Manzoor
- Antonina Mitrofanova (ORCID: https://orcid.org/0000-0003-0671-6512)
- Ikeer Y. Mancera-Ortiz (ORCID: https://orcid.org/0009-0005-7877-8562)
- Mu‐En Wang (ORCID: https://orcid.org/0000-0002-5953-3499)
- David H. Drewry (ORCID: https://orcid.org/0000-0001-5973-5798)
- Stefanie Howell (ORCID: https://orcid.org/0000-0003-3392-2848)
- Everardo Macias (ORCID: https://orcid.org/0000-0002-2846-4451)
- Ming Chen (ORCID: https://orcid.org/0000-0002-3470-1062)
- Yuzhuo Z. Wang (ORCID: https://orcid.org/0000-0002-9749-8591)
- Jung Wook Park (ORCID: https://orcid.org/0000-0002-3141-6207)
- Uran Maimekov
- Andrew J Armstrong
- Manasiben Patel
- Emily Cordova
Institutions
- Rutgers, The State University of New Jersey (US)
- University of North Carolina at Chapel Hill (US)
- Colorado State University Pueblo (US)
- St. Jude Children's Research Hospital (US)
- University of British Columbia (CA)
- Duke University (US)
- Augusta University (US)
- Vancouver General Hospital (CA)
- Duke Medical Center (US)
- Rutgers Health (US)
- Rutgers Cancer Institute (US)
- Duke Cancer Institute (US)
- UNC Lineberger Comprehensive Cancer Center (US)
- Vancouver Prostate Centre (CA)
Publication Details
- Journal
- Molecular Cancer
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1186/s12943-026-02838-9
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Pfizer
- Bayer
- McGill University
- Genome Canada
- Merck KGaA
- Ontario Genomics
- European Federation of Pharmaceutical Industries and Associations
- Ontario Genomics Institute
- Genentech
- National Cancer Institute
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
- Duke Cancer Institute
- DOD Prostate Cancer Research Program